Argenx Se · EURONEXT:ARGX
Argenx — Investor Presentation (November 2024)
28 slides from Argenx's investor presentation, November 2024
Slide 1: Reaching Patients Through Immunology Innovation
C O R P O R AT E P R E S E N TAT I O N | N O V E M B E R 2 0 2 4 Reaching Patients Through Immunology Innovation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Our Innovation Horizons
Our Innovation Horizons Empasiprubart ARGX-119 MMN Established PoC $573M net product revenue in Q3 2024 ARGX-109 CMS (Anti-IL-6) DGF CIDP launched ARGX-213 (Anti-FcRn) ALS DM ITP launched ARGX-121 (Anti-IgA) CIDP 5 registrational Future trials by YE 2024: Indications oMG, snMG, TED, SjD, ITP-US Futu
Slide 4: Building a Leading Immunology Company
Building a Leading Immunology Company Global Footprint Rooted in Science Reaching Patients Immunology Innovation Program Global clinical programs ongoing in Translating immunology breakthroughs into first-in-class pipeline opportunities Wholly-Owned Pipeline Efgartigimod Empasiprubart ARGX-119 FcRn
Slide 5: Our Innovation Playbook
Our Innovation Playbook Best-in-Field Pipeline-in- Novel Disease Antibody a-Product Biology Insights Engineering Development Foundational First-in-Class Differentiated Immune Antibodies Patient Targets Outcomes 5
Slide 6: Co-Creation is Our Innovation Formula
Co-Creation is Our Innovation Formula WORLD CLASS ANTIBODY DISEASE BIOLOGY INSIGHTS ENGINEERING CAPABILITY argenx Collaborators 6
Slide 7: VYVGART Horizon
VYVGART Horizon Empasiprubart ARGX-119 MMN Established PoC $573M net product revenue in Q3 2024 ARGX-109 CMS (Anti-IL-6) DGF CIDP launched ARGX-213 (Anti-FcRn) ALS DM ITP launched ARGX-121 (Anti-IgA) CIDP 5 registrational Future trials by YE 2024: Indications oMG, snMG, TED, SjD, ITP-US Future ARGX-
Slide 8: VYVGART is a Global Blockbuster
1000 On launch trajectory 950 900 to leading autoimmune 850 VYVGART 800 franchise is a Global 750 700 Blockbuster 650 600 VYVGART generated >$1B 550 in second year of launch 500 450 Approved in 3 indications globally 400 350 Leading market share among 300 MG branded biologics 250 200 150 100 50 0 L+
Slide 9: Product Net Sales: Q3 of $573 million
Product Net Sales: Q3 of $573 million 600 Product Net Sales by Quarter 573 Q3 2024: growth of 74% vs Q3 2023 550 (in millions of $) Q3 2024 Q3 2023 Growth % * 500 478 US 492 280 76% 450 Japan 24 15 49% $’m 398 400 ROW 46 26 76% 374 350 329 China supply 11 7 44% 300 Total 573 329 74% 269 250 218 200
Slide 10: Q3 2024 Financial Summary
Q3 2024 Financial Summary Summary P/L Three months ended Nine months ended Cash September 30 September 30 2024 2023 2024 2023 Product net sales 573 329 1,449 816 Collaboration revenue - 1 3 3 Other operating income 16 10 39 31 Ended third quarter 2024 Total operating income 589 340 1,491 851 with ca
Slide 11: Sustainability and Innovation Go Hand In Hand
Sustainability and Innovation Go Hand In Hand ESG Rating Performance Trends Sustainalytics ESG Risk Rating MSCI ESG rating Key ESG Initiatives Innovation leadership, access to medicine, people and development, relationships with suppliers and climate 11
Slide 12: Delivering Innovation Across VYVGART Globally
Delivering Innovation Across VYVGART Globally Driving impact with VYVGART Reaching Patients MG Rapid, deep, sustained responses achieved in patients CIDP Consistent responses and regain of function Globally with Functional Ability (aINCAT) VYVGART 54% 100 90 Efgartigimod PH20 SC MSE1 80 70 Franchise
Slide 13: Driving Patient Growth with VYVGART
Driving Patient Growth with VYVGART PATIENT GROWTH EARLIER LINE PATIENTS % 60 US Hytrulo patients new to VYVGART YTD 2 ~60% New VYVGART patients coming from orals 1 Expanding VYVGART Hytrulo share US patients PRESCRIBER EXPANSION PATIENT EXPERIENCE >3k Total VYVGART prescribers1 PFS PDUFA April 10th
Slide 14: Transforming the Patient Treatment Experience
Transforming the Patient Treatment Experience Pre-filled Syringe Autoinjector Approved June 2023 Filed June 2024 Industrialization phase Single 30-90s injection Increasingly convenient delivery Exclusive HCP administered Preparing for self-administration FcRn license High concentration formulation w
Slide 15: Executing on VYVGART Hytrulo Launch Priorities in CIDP
Executing on VYVGART Hytrulo Launch Priorities in CIDP Payors Physicians Patients Broad Early Delivering Access Enthusiasm Impact Favorable 72% >300 overlap MG and policies patients on treatment* CIDP physicians 54% 25% 85-90% commercial lives of patients coming new Hytrulo from IVIg prescribers *Pa
Slide 16: This is Just the Beginning
This is Just the Beginning Phase 3 studies 2024 PoC studies Beyond 2024 PoC studies sn gMG TED ITP-US Sjogren’s IMNM BP LN AMR SSc oMG 100K 57K 330K 6K 52K 40K 8K 60K ... ASyS 11K MG REMAINING READOUTS IN 2024 Launched 2022 DM 80K 70K Myositis Bullous Pemphigoid CIDP Approved June 21, 2024 42K ITP A
Slide 17: Opportunities Ahead Strengthen Our Leadership
Opportunities Ahead Strengthen Our Leadership 50K VYVGART Empasiprubart ARGX-119 BP CMS DM CIDP TED Sjögren’s Myositis MMN oMG 10K snMG CIDP ITP gMG Wave 1: TODAY Wave 2 (2026-2027) Wave 3 (2028-2030) 17
Slide 18: Pipeline Horizon
Pipeline Horizon VY VG AR Empasiprubart TO POC established in MMN ARGX-109 $573M net product Trials in DGF and DM ppo (Anti-IL-6) revenue in Q3 2024 rtuni Pip ARGX-213 CIDP launched (Anti-FcRn) elin ty e ITP launched ARGX-121 ARGX-119 Phase 1b/2a trials in CMS and ALS 5 registrational trials by YE 2
Slide 19: Rewriting Immunology Textbook with Empasiprubart
Rewriting Immunology Textbook with Empasiprubart Best-in-Field Pipeline-in- Novel Disease Antibody a-Product Biology Insights Engineering Development Unique Positioning MMN Disease Potent C2 Pioneering FcRn Biology Unique Modulation Long of FcRn Half-Life Pipeline-in-a-Product MMN, DGF, DM,Developme
Slide 20: Empasiprubart has Potential to Transform MMN
Empasiprubart has Potential to Transform MMN Cohort 1 Cohort 2 Reduced Reduced risk of IVIG risk of IVIG retreatment retreatment by by 91% 84% HR (95% CI) = 0.16 (0.02 ; 1.54) Empasiprubart Placebo Phase 3 to start in 4Q 2024 20
Slide 21: Empasiprubart Improved Grip Strength in Both Hands
Empasiprubart Improved Grip Strength in Both Hands IVIg Treatment → Clear Fluctuating Effect Grip Strength Grip Strength Change from baseline : mean (+/- SE) Grip Strength Change from baseline : mean (+/- SE) Patients at IVIG best 21
Slide 22: MMN: Opportunity to Build a Market
MMN: Opportunity to Build a Market MMN Today The argenx advantage Innovation Natural History Study to understand real-world experience 10K Engagement with patients More Innovation = More Prescribers, Co-creation Better Outcomes For Patients PATIENTS Deep existing neurology Execution relationships 22
Slide 23: ARGX-119: Enhancing Neuromuscular Junction through MuSK Activation
ARGX-119: Strengthening Enhancing Neuromuscular the Neuromuscular Junction throughJunction MuSK Activation Best-in-Field Pipeline-in- Novel Disease Antibody a-Product Biology Insights Engineering Development CMS, ALS Innovative Endpoint Pioneering MuSK Biology Best-in-Field Antibody Engineering Stud
Slide 24: CMS and ALS Trials Started
CMS and ALS Trials Started ARGX-119 rescues early neonatal lethality and ARGX-119 slows muscle denervation disease relapse in adult DOK7 CMS mice and improves motor function Slowdown of muscle denervation Improving motor system output n=6 animals per group, faint grey and blue lines indicate the SEM
Slide 25: Immunology Innovation Horizon
Immunology Innovation Horizon VY VG AR Empasiprubart TO POC established in MMN ARGX-109 $573M net product Trials in DGF and DM ppo (Anti-IL-6) revenue in Q3 2024 rtuni Pip ARGX-213 CIDP launched (Anti-FcRn) elin ty e ITP launched ARGX-121 ARGX-119 Phase 1b/2a trials in CMS and ALS 5 registrational t
Slide 26: Pipeline Growth Driven By Immunology Innovation Program
Pipeline Growth Driven By Immunology Innovation Program Internal External Value Creation CLINICAL DISEASE Value Creation DEVELOPMENT INSIGHT LEO Agomab Efgartigimod Empasiprubart (ARGX-112) (ARGX-114) AbbVie ARGX-119 ARGX-121 LEADING ARGX-118 (ARGX-115) TRANSLATIONAL BIOLOGY LABS ARGX-213 OncoVerity
Slide 27: Strong Cadence of Milestones in 2024
Strong Cadence of Milestones in 2024 Indication Milestone Timing Decision on approval: Switzerland, Australia, Saudi Arabia By Year End gMG VYVGART Seronegative trial initiation By Year End ✓ ITP Approved in Japan March 26, 2024 ✓ Approved in Japan as VYVDURA Jan 18, 2024 ✓ gMG China decision on app
Slide 28: Vision 2030
Vision 2030 5 New Molecules in Phase 3 10 Labeled Indications 50 K Patients on Treatment COMMITMENT TO OUR TRANSFORMATION MISSION Continuous Pipeline of Leadership in FcRn Disciplined Scaling Innovation 28